Medicare annual wellness visit (AWV) reimbursement rate change 2022
Jan. 2022Important Notices
UPMC Health Plan is working to promote the health of our Medicare members through the Medicare annual wellness visit (AWV). This visit is integral to our members’ health as it can be used as an opportunity for gap closure.
Effective Jan. 1, 2022, reimbursement for the annual wellness visit (AWV) will be adjusted and UPMC Health Plan will continue to pay above the Medicare fee schedule.
HCPCS/CPT code | Reimbursement Rate |
G0438 | $200 |
G0439 | $175 |
To be eligible, the visit must be coded as a wellness visit ONLY (G0438 or G0439). The visit must be conducted within CMS-defined parameters and with appropriate clinical documentation in the medical record. Claims are subject to a UPMC Health Plan audit.
Please contact your physician account executive or call Provider Services at 1-866-918-1595 (TTY: 711) if you have any questions. Thank you for your continued support of our members.
The provider of care is ultimately responsible for providing accurate and compliant information on all submission of claims and/or billing information.
Recent Announcements
Important announcement – Telehealth submissions
As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.Sep. 2025Important Notices
October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update
Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.Sep. 2025Pharmacy Updates
Biosimilar Medication Formulary Updates
Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab productsSep. 2025Pharmacy Updates